{"id":"fimasartan-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1951143","moleculeType":"Small molecule","molecularWeight":"501.66"},"_fixedAt":"2026-03-30T16:37:43.860981","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fimasartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and other tissues, causing vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urine output and reducing blood volume. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:35.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT05413057","phase":"","title":"An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-06-23","conditions":"Hypertension,Essential","enrollment":20000},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":"The Elderly (≥ 70 Years) With Essential Hypertension","enrollment":241},{"nctId":"NCT03629067","phase":"PHASE1","title":"Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-09-13","conditions":"Pharmacokinetics","enrollment":60},{"nctId":"NCT03390465","phase":"PHASE1","title":"Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-12-15","conditions":"Drug-Drug Interaction","enrollment":36},{"nctId":"NCT02222480","phase":"PHASE2","title":"A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2014-10","conditions":"Hypertension","enrollment":103},{"nctId":"NCT02466490","phase":"PHASE3","title":"Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Stendhal Americas, S.A.","startDate":"2013-04","conditions":"Hypertension, Essential","enrollment":272},{"nctId":"NCT01258673","phase":"PHASE3","title":"A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2010-11","conditions":"Essential Hypertension","enrollment":263},{"nctId":"NCT00923533","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2015","pmid":"26082615","title":"Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.","journal":"Drug design, development and therapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Diarakhor","Kanarb plus"],"phase":"phase_3","status":"active","brandName":"Fimasartan; Hydrochlorothiazide","genericName":"Fimasartan; Hydrochlorothiazide","companyName":"Stendhal Americas, S.A.","companyId":"stendhal-americas-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}